ELTP OTC
Elite Pharmaceuticals, Inc.
1W: -11.4%
1M: -17.2%
3M: -37.6%
YTD: -54.3%
1Y: -65.6%
3Y: +154.1%
5Y: +357.3%
$0.23
+0.00 (+0.73%)
Weekly Expected Move ±6.3%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships6
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-12-02
Earliest Filing
2024-06-21
Latest Filing
partner: 4
target: 1
customer: 1
Counterparties (Filed by ELTP)
6 relationshipsCompanies named in ELTP's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Nostrum Laboratories Inc. | — | target | Sold rights to ANDAs for generic Norco, Percocet, and Dolophine and licensed manufacturing technology to Elite Pharmaceu | 2024-06-21 | View |
| Pyros Pharmaceuticals, Inc. | — | customer | Elite Pharmaceuticals sold rights to ANDAs for generic Sabril and entered a manufacturing supply agreement. | 2022-11-28 | View |
| Dexcel Ltd. | — | partner | Exclusive distributor for Elite's generic Adderall in Israel | 2021-12-09 | View |
| Mikah Pharma LLC | — | partner | Joint owner of Elite's generic Adderall product | 2021-12-09 | View |
| Lannett Company, Inc. | — | partner | Elite Pharmaceuticals renewed a License, Supply and Distribution Agreement with Lannett to market generic Dantrolene Cap | 2021-12-02 | View |
| Lannett Company, Inc. | — | partner | Elite Pharmaceuticals renewed a license, supply, and distribution agreement with Lannett to market two generic Adderall | 2021-12-02 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-13 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-08-11 | Regulation FD; Exhibits | View | |
| 2026-08-10 | Regulation FD; Exhibits | View | |
| 2026-08-04 | Regulation FD; Exhibits | View | |
| 2026-06-29 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-06-23 | Regulation FD; Exhibits | View | |
| 2026-06-15 | Regulation FD; Exhibits | View | |
| 2026-06-01 | Regulation FD; Exhibits | View | |
| 2026-04-02 | Regulation FD; Exhibits | View | |
| 2026-02-17 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-02-11 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-14 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-10 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-14 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-08-08 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-06-30 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-06-23 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-06-16 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR